title: Anti-adipogenic effects of 1,25-dihydroxyvitamin D3 are mediated by             the maintenance of the wingless-type MMTV integration site/β-catenin pathway.
abstract: 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), the active metabolite of vitamin             D, was found to have anti-adipogenic activity, however, its mechanism of action             has not been fully elucidated. In this study, 3T3-L1 preadipocytes were differentiated             in the presence and absence of 1,25(OH)2D3, and the expression of the genes and             proteins of the wingless-type MMTV integration site (WNT)/β-catenin pathway were             analyzed. While the expression of the members of the WNT/β-catenin pathway were             significantly downregulated during the adipogenesis of untreated 3T3-L1 cells,             1,25(OH)2D3 treatment was found to maintain the WNT/β-catenin pathway. Among the             members of the WNT/β-catenin pathway, the levels of WNT10B and disheveled (DVL)2             as well as the phosphorylation of glycogen synthase kinase (GSK)3β were maintained             by 1,25(OH)2D3 treatment. The levels of nuclear β-catenin, which were downregulated             during adipogenesis, were also maintained by 1,25(OH)2D3 treatment. The results             of this study suggested that the anti-adipogenic effect of 1,25(OH)2D3 was mediated             by the maintenance of the WNT/β-catenin pathway, which was normally downregulated             during adipogenesis.
authors.affiliation: Department of Microbiology, Chung-Ang University College of Medicine,                     Seoul 156-756, Republic of Korea.
authors.forename: Haeyong
authors.initials: H
authors.lastname: Lee
authors.forename: Sungmin
authors.initials: S
authors.lastname: Bae
authors.forename: Yoosik
authors.initials: Y
authors.lastname: Yoon
mesh_terms: D041721:3T3-L1 Cells; D048868:Adaptor Proteins, Signal Transducing / Q000235:genetics / Q000378:metabolism; D050156:Adipogenesis / Q000187:drug effects*; D000818:Animals; D019440:Anti-Obesity Agents / Q000494:pharmacology*; D022762:CCAAT-Enhancer-Binding Proteins / Q000235:genetics / Q000378:metabolism; D002117:Calcitriol / Q000494:pharmacology*; D002467:Cell Nucleus / Q000378:metabolism; D000072261:Dishevelled Proteins; D050556:Fatty Acid-Binding Proteins / Q000235:genetics / Q000378:metabolism; D015870:Gene Expression / Q000187:drug effects; D008071:Lipoprotein Lipase / Q000235:genetics / Q000378:metabolism; D060488:Low Density Lipoprotein Receptor-Related Protein-6 / Q000235:genetics / Q000378:metabolism; D051379:Mice; D047495:PPAR gamma / Q000235:genetics / Q000378:metabolism; D010750:Phosphoproteins / Q000235:genetics / Q000378:metabolism; D051153:Wnt Proteins / Q000235:genetics / Q000378:metabolism; D060449:Wnt Signaling Pathway / Q000187:drug effects*; D051176:beta Catenin / Q000235:genetics / Q000378:metabolism
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D019440:Anti-Obesity Agents; D022762:CCAAT-Enhancer-Binding Proteins; C530718:CEBPA protein, mouse; D000072261:Dishevelled Proteins; C000606582:Dvl2 protein, mouse; C493411:Fabp4 protein, mouse; D050556:Fatty Acid-Binding Proteins; D060488:Low Density Lipoprotein Receptor-Related Protein-6; C555476:Lrp6 protein, mouse; D047495:PPAR gamma; D010750:Phosphoproteins; D051153:Wnt Proteins; C102068:Wnt10b protein, mouse; D051176:beta Catenin; D008071:Lipoprotein Lipase; D002117:Calcitriol